All In Biotech

Investigational drug · Phase 2

MT101-5

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "MT101-5"

First trial start

2027

Sep 2027

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MT101-5", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Parkinson's Disease

Approved drugs for the same conditions: Parkinson's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "MT101-5" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Parkinson's Disease

  • PrasinezumabRO7046015, PRX002Phase 33 trials

    Roche (Genentech) · Parkinson's Disease, Parkinsons Disease

  • CVN424Phase 32 trials

    Cerevance · Parkinson Disease, Parkinson's Disease

  • GM1Phase 32 trials

    Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease

  • iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials

    XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy

  • RO7568282Phase 22 trials

    Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease

  • BIA 28-6156Phase 21 trial

    Bial R&D Investments, S.A. · Parkinson's Disease

  • ND0612ND0612HPhase 21 trial

    NeuroDerm Ltd. · Parkinson's Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.